Related Experiment Videos
Comparison between low-dose simvastatin and cholestyramine in moderately severe hypercholesterolemia
1Department of Endocrinology, Internal Medicine, University Hospital of Ghent, Belgium.
Acta Cardiologica
|January 1, 1989
Summary
Simvastatin (10 mg) effectively lowered cholesterol compared to cholestyramine in a 6-week study. This new HMG-CoA reductase inhibitor demonstrated superior lipid-lowering effects and better patient tolerance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypercholesterolemia management requires effective lipid-lowering agents.
- HMG-CoA reductase inhibitors represent a novel therapeutic class.
Purpose of the Study:
- To compare the efficacy and tolerance of simvastatin versus cholestyramine.
- Evaluate simvastatin's impact on lipid profiles and cardiovascular risk markers.
Main Methods:
- A 6-week multicenter study involving 145 patients with elevated cholesterol.
- Patients received either 10 mg simvastatin or 12 g cholestyramine after a standard diet.
Main Results:
- Simvastatin reduced total cholesterol by 21% vs. 16% for cholestyramine (p<0.01).
- LDL cholesterol decreased by 30% with simvastatin vs. 25% with cholestyramine.
- Simvastatin improved HDL cholesterol and reduced Total:HDL and LDL:HDL ratios more significantly, with fewer adverse events.
Conclusions:
- 10 mg simvastatin is as effective as 12 g cholestyramine in lowering cholesterol.
- Simvastatin offers improved lipid profile modification and better tolerability.